Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Academic Article 2019 uri icon

authors

  • Gatell JM
  • Harvey C
  • Xu X
  • Plettenberg A
  • Smith DE
  • PORTILLA SOGORB, JOAQUIN
  • Rugina S
  • Kumar S
  • Frobose C
  • Wan H
  • Rodgers A
  • Morales-Ramirez JO
  • Hwang C
  • Teppler H
  • Hagins DP
  • Thompson M
  • Arastéh K
  • Hoffmann C
  • Raffi F
  • Osiyemi O
  • Dretler R

publication date

  • 2019